Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844076 · ClinicalTrials.gov registry record · Phase 1
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01844076 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 19 participants.
The verdict
NCT01844076, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Establish the tolerability and safety of aimed dose of both quinacrine and capecitabine in combination to treat patients with advanced colorectal adenocarcinoma.
Interventions
- DRUG Quinacrine and Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-01-14 |
| Est. Completion | 2019-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01844076
The ClinicalTrials.gov registry entry for NCT01844076 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quinacrine and Capecitabine is the first listed.
NCT01844076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01844076 about?
NCT01844076 is a clinical study titled "Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma". Establish the tolerability and safety of aimed dose of both quinacrine and capecitabine in combination to treat patients with advanced colorectal adenocarcinoma.
What is the current status of trial NCT01844076?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2016-01-14. Estimated completion is 2019-08-09.
What interventions are being tested in trial NCT01844076?
The interventions under investigation include: Quinacrine and Capecitabine (DRUG).
Who is sponsoring clinical trial NCT01844076?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.